# "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

> **NCT02074657** · PHASE2 · COMPLETED · sponsor: **Hospital Universitario La Paz** · enrollment: 13 (actual)

## Conditions studied

- Relapsed/Refractory Paediatric Acute Leukaemia

## Interventions

- **BIOLOGICAL:** Activated and expanded natural killer cells (NKAEs)

## Key facts

- **NCT ID:** NCT02074657
- **Lead sponsor:** Hospital Universitario La Paz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02074657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02074657, ""LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02074657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*